ANDA 201831, held by Glenmark Pharmaceuticals. Desmopressin Acetate.
As of Nov 21, 2026, ANDA 201831 (Desmopressin Acetate), held by Glenmark Pharmaceuticals, was first approved by FDA on May 28, 2015, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 28, 2015 | Original application | Approved |
| Desmopressin Acetate0.1MG · tablet;oral | Desmopressin Acetate | Discontinued |
| Desmopressin Acetate0.2MG · tablet;oral | Desmopressin Acetate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters